Evaluate’s pharmaceutical consulting and analytics team is here to help clients address unique scientific, clinical and commercial challenges. We answer key asset, portfolio, and corporate strategy-related business questions, powered by the combined resources of Norstella, one of the world’s largest pharma intelligence solutions providers.
With a team of over 70 consultants globally, extensive data assets, and experience across therapy areas and modalities, we specialise in the areas of Portfolio Strategy, Licensing and Transaction Advisory and Competitive Intelligence.
Your unique commercial and clinical decisions require a partner who understands your business. Evaluate’s combination of leading data sources, deep pharma expertise, robust methodologies, data science and real-world data will ensure your teams make the right decisions to drive your growth.
How can you objectively determine the true worth of acquisition and licensing targets and accurately assess the health of your portfolio? Our team can provide insights to enable informed portfolio strategy decisions. We can help you with tailored:
Competition in biopharma is fierce. Evaluate’s CI practice provides clinical and commercial teams with the support to understand their evolving competitive landscape and to facilitate strategic decision making. We help with:
Our experts partner with clients to address business questions throughout the BD&L process. They streamline decision-making to build commercially-focused pipelines and help address the balance between internal and external innovation, offering;
Leveraging a foundation of extensive Evaluate data, augmented with secondary research, modelling and analysis, our pharmaceutical consulting solutions are data-driven and insight-focused. We also conduct targeted primary research with key opinion leaders, healthcare professionals and payers to validate our assumptions and test our hypotheses.
As part of Norstella, our team has access to an unparalleled range of insights, expertise and deep industry knowledge.
Evaluate makes it possible for us to assess the commercial value for different products, as well as understand the major trends in the pharmaceutical industry.
Paul leads the Evaluate Consulting and Analytics business and has 20 years’ experience across research and consulting, spanning asset strategy, portfolio strategy, competitive intelligence, and BD&L. Paul has worked with a range of organisations across the pharma ecosystem including start-up biotechs seeking perspectives into product strategy, suppliers and partners who need insight into potential customers, and large pharma groups navigating complex R&D and commercial challenges. Paul holds a PhD in Neuropharmacology.
Mark leads Evaluate’s Asset and Portfolio strategy practice area and has more than 20 years’ experience in pharmaceuticals and healthcare, initially as a scientist in academia and big pharma, and subsequently in analyst and consulting roles. Mark has worked with a variety of clients on projects delivering opportunity assessment, indication prioritisation, optimisation of development strategy, product positioning, product forecasts, and valuations across numerous therapy areas. Mark gained a PhD in Organic Chemistry from the University of Leeds.
Ben has over 10 years’ life sciences consulting experience, with a specialism in quantitative analysis. He has led projects assessing probability of technical success, pipeline tracking, competitor analysis and product forecasting across a range of indications and markets, with an increasing focus on rare diseases. Ben holds a BSc in Microbiology from the University of Leeds and a PhD in Molecular Microbiology and Analytical Chemistry from the University of Essex.
Sheila leads the clinical practice area and has over 10 years’ medical, life sciences and healthcare industry experience. She has worked across a wide range of therapy areas with a key focus on clinical trial optimisation. Sheila previously held various roles within clinical operations, development, commercialisation and strategic consulting, having started her career as a registered nurse and before moving to the clinical research industry. Sheila holds a Bachelor in Biochemistry, and is fluent in German and Swahili.
Xin is the global value and access lead for the Consulting and Analytics team with over 15 years’ experience across academia, pharma and medtech, and consulting. Her expertise lies within global market access, pricing, and reimbursement strategy for both early-stage assets and late-stage assets. Xin has worked with multiple therapy areas such as oncology, respiratory, immunotherapy, rare diseases, and neurological disorders. Xin has an MSc in Applied Biomolecular Technology, a PhD in Immunology, and an executive certification in Brand and Product Strategy (Imperial College).